NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to Discuss “Shape-Shifting”, “Trojan Horse”, Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR
SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President and Executive Chairman, has been invited and will be presenting a talk at the Global AMR Summit, which is being held at the Kimpton Marlowe Hotel, Cambridge, MA, tomorrow, October 9, 2024.
AMR, or “Anti-Microbial Resistance” leads to the failure of antibiotic therapy in bacteria, yeasts, fungi, and other human pathogens, as these pathogens have been evolving to escape the anti-microbial drugs developed against them.
Dr. Diwan will present NanoViricides’ “Trojan Horse” Platform Technology that enables delivery of one or more “war-heads” against a pathogen directly onto the pathogen, sparing normal host cells. This pathogen-directed therapy is expected to result in reduced toxicity and improved pharmacokinetics for the anti-microbial war-heads encapsulated within the nanoviricide micelle.
“The ‘shape-shifting’ nanoviricide™ platform technology opens up new avenues for combatting anti-microbial resistance,” commented Dr. Diwan, adding, “We have already developed nanoviricide drugs against viruses that promise to combat the problem of viral escape from a drug. We believe this technology can be applied to develop novel anti-microbial drugs in order to solve the AMR problem.”
The global Antibiotic Resistance Market size was valued at USD 8.98 billion in 2022 and is poised to grow from USD 10.16 billion in 2023 to USD 27.39 billion by 2031, growing at a CAGR of 13.19% during the forecast period (2024-2031), according to a Skyquest Market Report (https://www.skyquestt.com/report/antibiotic-resistance-market).
The Company’s lead drug, NV-387, a broad-spectrum host-mimetic antiviral, has successfully completed Phase 1a/1b human clinical trials in healthy subjects, with no reported adverse events, indicating excellent safety and tolerability.
The same drug NV-387 has demonstrated strong antiviral activity against viruses from multiple families, including Coronaviruses (SARS-CoV-2, Long COVID, Seasonal coronaviral infections), RSV, Influenza A, as well as a Smallpox/Mpox related mouse virus in stringent, lethal viral infection animal models. In all of these cases, NV-387 led to improvement in survival that substantially exceeded or was at least on par with that from already approved drugs or known antiviral agents.
The host-mimetic design of the nanoviricide NV-387 is expected to make escape of viruses from the drug highly unlikely, thus solving the major problem in development of antiviral countermeasures.
NV-387 could be the very first single drug that can treat all of the “tripledemic” viral infections, namely, Coronaviruses, RSV, and Influenza A.
In addition, the Company is also developing “dual-action” nanoviricides that promise to completely cure viral infections by virtue of attacking both the “Re-Infection” part as well as the “Replication” part, thus blocking the complete Virus Life Cycle, by exploiting the “shape-shifting”, and “Trojan-Horse” capabilities of the nanoviricide technology platform.
About Global AMR Summit 2024: The Premier Forum for Antimicrobial Resistance and Global Public Health
Welcome to the Global AMR Summit 2024, where global biotechnology and pharmaceutical companies will meet with leading experts and researchers in Boston, Massachusetts, to discuss the causes and response to antibiotic resistance and to understand the value of novel antibiotics to address the threat of AMR to public health.
Antimicrobial Resistance (AMR) is a serious and growing concern to global public health, with 1.5 million deaths annually. Due to the escalation of Antibiotic Resistance Pathogenic Bacteria (ARPB) and Multi-Drug Resistance (MDR) in pathogenic bacteria, public health is returning to the “pre-antibiotic era” because of the non-effectiveness of present antibiotics against bacterial infections. The lack of rapid diagnostics and poor infection prevention control has transformed AMR into a global public health threat.
Next-generation antimicrobials and vaccines to combat the ‘silent pandemic’ of antimicrobial resistance are on the priority list of global healthcare. Embracing new technologies, such as disrupting protein folding, photodynamic therapy, antimicrobial peptides, and AI-based antibiotics, will help overcome the challenges of Antimicrobial Resistance.
This year’s Global AMR Summit will become the world’s leading exhibition and conference exclusively for pharmaceutical and biotechnology companies to address scientific and business solutions in next-generation antimicrobials and vaccines to combat antimicrobial resistance.
This event will provide a forum for global pharmaceutical and biotechnology stakeholders to network and build cross-market relationships to explore new technologies and technical know-how to address the challenges in antimicrobial and antimicrobial resistance.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc., info@nanoviricides.com
Public Relations Contact: ir@nanoviricides.com
SOURCE: NanoViricides, Inc.
View the original press release on accesswire.com
